Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
13
×
life sciences
national blog main
san francisco blog main
13
×
clinical trials
san francisco top stories
boston blog main
boston top stories
new york blog main
new york top stories
national top stories
eli lilly
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
seattle blog main
seattle top stories
texas blog main
texas top stories
cancer immunotherapy
deals
investing
medical device
startups
johnson & johnson
medicare
merck
migraine
What
companies
13
×
drug
ipo
life
new
bio
roundup
science
week
biotech
leading
medicines
street
therapeutics
wall
approval
black
days
diamond
disease
fda
hasn’t
haul
ipos
latest
led
migraine
momentum
nash
news
price
public
raised
research
satsuma
sciences
slowed
springworks
therapies
welcomed
Language
unset
Current search:
biotech
×
companies
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M